The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy

Nature Medicine

Volumn 22, Issue 10, 2016, Pages 1131-1139

  Wang, Zhihua ^a,b,c,d   Zhang, Xiao Jing ^a,b,c   Ji, Yan Xiao ^a,b,c   Zhang, Peng ^a,b,c   Deng, Ke Qiong ^a,b,c   Gong, Jun ^a,b,c   Ren, Shuxun ^c   Wang, Xinghua ^e   Chen, Iris ^d   Wang, He ^d   Gao, Chen ^d   Yokota, Tomohiro ^d   Ang, Yen Sin ^f,g   Li, Shen ^d   Cass, Ashley ^d,h   Vondriska, Thomas M ^d   Li, Guangping ^e   Deb, Arjun ^d   Srivastava, Deepak ^f,g   Yang, Huang Tian ^i,j   Xiao, Xinshu ^d,h   Li, Hongliang ^a,b,c   Wang, Yibin ^d   more..

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^f GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Chinese Academy of Sciences   (China)

^j SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; LONG NONCODING RNA CHAER; LONG UNTRANSLATED RNA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; EPIGENETICS; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; GENE LOCUS; GENOMICS; HEART VENTRICLE HYPERTROPHY; HISTONE METHYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; STRESS; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CHROMATIN IMMUNOPRECIPITATION; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HEART; HISTONE CODE; IMMUNOBLOTTING; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; KNOCKOUT MOUSE; METABOLISM; METHYLATION; NORTHERN BLOTTING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOTTING, NORTHERN; CARDIOMEGALY; CHROMATIN IMMUNOPRECIPITATION; COMPUTER SIMULATION; ECHOCARDIOGRAPHY; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HEART; HISTONE CODE; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION, FLUORESCENCE; IN VITRO TECHNIQUES; INDUCED PLURIPOTENT STEM CELLS; METHYLATION; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; MYOCARDIUM; MYOCYTES, CARDIAC; POLYCOMB REPRESSIVE COMPLEX 2; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; TOR SERINE-THREONINE KINASES;

EID: 84987600948     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4179     Document Type: Article

References (71)

1. Sala, V. et al. Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol. Med. 18, 938-947 (2012).
2. Kuwahara, K., Nishikimi, T. & Nakao, K. Transcriptional regulation of the fetal cardiac gene program. J. Pharmacol. Sci. 119, 198-203 (2012).
3. Wang, Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116, 1413-1423 (2007).
4. Maron, B. J. & Maron, M. S. Hypertrophic cardiomyopathy. Lancet 381, 242-255 (2013).
5. Joh, R. I., Palmieri, C. M., Hill, I. T. & Motamedi, M. Regulation of histone methylation by noncoding RNAs. Biochim. Biophys. Acta 1839, 1385-1394 (2014).
6. Gould, A. Functions of mammalian Polycomb group and trithorax group-related genes. Curr. Opin. Genet. Dev. 7, 488-494 (1997).
7. Kaneda, R. et al. Genome-wide histone methylation profile for heart failure. Genes Cells 14, 69-77 (2009).
8. Angrisano, T. et al. Epigenetic switch at Atp2a2 and Myh7 gene promoters in pressure-overload-induced heart failure. PLoS One 9, e106024 (2014).
9. Papait, R. et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 110, 20164-20169 (2013).
10. Ishii, N. et al. Identification of a novel noncoding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet. 51, 1087-1099 (2006).
11. Friedrichs, F. et al. HBEGF, SRA1 and IK: Three co-segregating genes as determinants of cardiomyopathy. Genome Res. 19, 395-403 (2009).
12. Burd, C. E. et al. Expression of linear and novel circular forms of an INK4/ARF-associated noncoding RNA correlates with atherosclerosis risk. PLoS Genet. 6, e1001233 (2010).
13. Kumarswamy, R. et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ. Res. 114, 1569-1575 (2014).
14. Wang, K. et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 114, 1377-1388 (2014).
15. Jiang, F., Zhou, X. & Huang, J. Long noncoding RNA-ROR mediates the reprogramming in cardiac hypertrophy. PLoS One 11, e0152767 (2016).
16. Viereck, J. et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci. Transl. Med. 8, 326ra22 (2016).
17. Liu, L. et al. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc. Res. 111, 56-65 (2016).
18. Peters, T. et al. Long noncoding RNA Malat-1 is dispensable during pressure-overload-induced cardiac remodeling and failure in mice. PLoS One 11, e0150236 (2016).
19. Matkovich, S. J., Edwards, J. R., Grossenheider, T. C., de Guzman Strong, C. & Dorn, G. W., II. Epigenetic coordination of embryonic heart transcription by dynamically regulated long noncoding RNAs. Proc. Natl. Acad. Sci. USA 111, 12264-12269 (2014).
20. Ounzain, S. et al. Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long noncoding RNAs. Eur. Heart J. 36, 353-68a (2015).
21. Grote, P. et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev. Cell 24, 206-214 (2013).
22. Lee, J. H. et al. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ. Res. 109, 1332-1341 (2011).
23. Kurian, L. et al. Identification of novel long noncoding RNAs underlying vertebrate cardiovascular development. Circulation 131, 1278-1290 (2015).
24. Wang, Z. & Wang, Y. Dawn of the Epi-LncRNAs: new path from Myheart. Circ. Res. 116, 235-236 (2015).
25. Li, L. et al. Targeted disruption of Hotair leads to homeotic transformation and gene de-repression. Cell Rep. 5, 3-12 (2013).
26. Klattenhoff, C. A. et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152, 570-583 (2013).
27. Wang, K. C. et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120-124 (2011).
28. Liu, Z. et al. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21WAF1/CIP1 expression. PLoS One 8, e77293 (2013).
29. Li, F. et al. Characterization of sucrose transporter alleles and their association with seed-yield-related traits in Brassica napus L. BMC Plant Biol. 11, 168 (2011).
30. Han, P. et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102-106 (2014).
31. Kallen, A. N. et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol. Cell 52, 101-112 (2013).
32. Monnier, P. et al. H19 lncRNA controls gene expression of the Imprinted Gene Network by recruiting MBD1. Proc. Natl. Acad. Sci. USA 110, 20693-20698 (2013).
33. Finn, R. D. et al. Pfam: The protein families database. Nucleic Acids Res. 42, D222-D230 (2014).
34. Chu, C., Qu, K., Zhong, F. L., Artandi, S. E. & Chang, H. Y. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol. Cell 44, 667-678 (2011).
35. Leppek, K. & Stoecklin, G. An optimized streptavidin-binding RNA aptamer for purification of ribonucleoprotein complexes identifies novel ARE-binding proteins. Nucleic Acids Res. 42, e13 (2014).
36. Wu, L., Murat, P., Matak-Vinkovic, D., Murrell, A. & Balasubramanian, S. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry 52, 9519-9527 (2013).
37. Kang, S., Chemaly, E. R., Hajjar, R. J. & Lebeche, D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) and c-Jun N-terminal kinase-insulin receptor substrate 1 (JNK-IRS1) pathways. J. Biol. Chem. 286, 18465-18473 (2011).
38. Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008).
39. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
40. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302 (2004).
41. Li, Q., Wang, P., Ye, K. & Cai, H. Central role of SIAH inhibition in DCC-dependent cardioprotection provoked by netrin-1-NO. Proc. Natl. Acad. Sci. USA 112, 899-904 (2015).
42. Cabili, M. N. et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25, 1915-1927 (2011).
43. Delgado-Olguín, P. et al. Epigenetic repression of cardiac progenitor gene expression by EZH2 is required for postnatal cardiac homeostasis. Nat. Genet. 44, 343-347 (2012).
44. Yang, T. et al. MicroRNA-214 provokes cardiac hypertrophy via repression of EZH2. Biochem. Biophys. Res. Commun. 436, 578-584 (2013).
45. Shi, L. et al. Histone demethylase JMJD2B coordinates H3K4 and H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. USA 108, 7541-7546 (2011).
46. Agger, K. et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449, 731-734 (2007).
47. Song, X. et al. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am. J. Physiol. Cell Physiol. 299, C1256-C1266 (2010).
48. Liu, X., Wang, X., Bi, Y., Bu, P. & Zhang, M. The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload. Exp. Cell Res. 335, 123-134 (2015).
49. Xu, N. et al. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signaling and leads to chronic heart failure. J. Pathol. 235, 672-685 (2015).
50. Li, Y. et al. AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Arch. Biochem. Biophys. 558, 79-86 (2014).
51. Shende, P. et al. Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy. Cardiovasc. Res. 109, 103-114 (2016).
52. Shende, P. et al. Cardiac Raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression and causes heart failure in mice. Circulation 123, 1073-1082 (2011).
53. Kaneko, S. et al. Phosphorylation of the PRC2 component EZH2 is cell-cycle-regulated and upregulates its binding to ncRNA. Genes Dev. 24, 2615-2620 (2010).
54. Marketou, M. E., Parthenakis, F. & Vardas, P. E. Pathological left ventricular hypertrophy and stem cells: current evidence and new perspectives. Stem Cells Int. 2016, 5720758 (2016).
55. National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).
56. MacLellan, W. R., Xiao, G., Abdellatif, M. & Schneider, M. D. A novel Rb-and p300-binding protein inhibits transactivation by MyoD. Mol. Cell. Biol. 20, 8903-8915 (2000).
57. van Laake, L. W. et al. Reporter-based isolation of induced pluripotent stem cell-and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circ. Res. 107, 340-347 (2010).
58. Ubil, E. et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 514, 585-590 (2014).
59. Zhou, Y. Y. et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am. J. Physiol. Heart Circ. Physiol. 279, H429-H436 (2000).
60. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR-Cas-mediated genome engineering. Cell 153, 910-918 (2013).
61. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
62. Komurov, K., Dursun, S., Erdin, S. & Ram, P. T. NetWalker: A contextual network analysis tool for functional genomics. BMC Genomics 13, 282 (2012).
63. Lu, G. et al. Protein phosphatase 2Cm is a critical regulator of branched-chain amino acid catabolism in mice and cultured cells. J. Clin. Invest. 119, 1678-1687 (2009).
64. Nekrasov, M., Wild, B. & Müller, J. Nucleosome-binding and histone methyltransferase activity of Drosophila PRC2. EMBO Rep. 6, 348-353 (2005).
65. Baroni, T. E., Chittur, S. V., George, A. D. & Tenenbaum, S. A. Advances in RIP-chip analysis: RNA-binding protein immunoprecipitation-microarray profiling. Methods Mol. Biol. 419, 93-108 (2008).
66. Leppek, K. & Stoecklin, G. An optimized streptavidin-binding RNA aptamer for purification of ribonucleoprotein complexes identifies novel ARE-binding proteins. Nucleic Acids Res. 42, e13 (2014).
67. Sdek, P. et al. Rb and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes. J. Cell Biol. 194, 407-423 (2011).
68. Young, M. D. et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 39, 7415-7427 (2011).
69. Streicher, J. M., Kamei, K., Ishikawa, T. O., Herschman, H. & Wang, Y. Compensatory hypertrophy induced by ventricular-cardiomyocyte-specific COX-2 expression in mice. J. Mol. Cell. Cardiol. 49, 88-94 (2010).
70. Mitchell-Jordan, S. A. et al. Loss of Bmx nonreceptor tyrosine kinase prevents pressure-overload-induced cardiac hypertrophy. Circ. Res. 103, 1359-1362 (2008).
71. Jiang, D. S. et al. Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 63, 713-722 (2014).